Preclinical evaluation and automated synthesis of [89Zr]ZrDFOSquaramide-girentuximab for diagnostic imaging of carbonic anhydrase IX positive tumours
[<sup>89</sup>Zr]ZrDFOSq-girentuximab has high uptake in CAIX positive tumours. An automated procedure for the synthesis of [<sup>89</sup>Zr]ZrDFOSq-girentuximab using [<sup>89</sup>Zr]ZrCl<sub>4</sub> as a starting material has been developed. This automated process could be readily adapted to other antibodies.
Authors
- Peter D. Roselt (ORCID: https://orcid.org/0000-0003-2310-5377)
- Jessica Van Zuylekom (ORCID: https://orcid.org/0000-0002-2498-5946)
- Michael P. Wheatcroft (ORCID: https://orcid.org/0009-0003-3145-0792)
- Rodney J. Hicks (ORCID: https://orcid.org/0000-0002-0758-0824)
- Carleen Cullinane (ORCID: https://orcid.org/0000-0001-5833-6605)
- Asif Noor (ORCID: https://orcid.org/0000-0001-5713-6070)
- Emily R. McGowan
- Paul S. Donnelly (ORCID: https://orcid.org/0000-0001-5373-0080)
Institutions
- Biotechnology Institute (US)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
Publication Details
- Journal
- EJNMMI Radiopharmacy and Chemistry
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1186/s41181-024-00310-x
- Citations
- 2
- Primary Topic
- Enzyme function and inhibition
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Australian Cancer Research Foundation
- Peter MacCallum Cancer Centre
- Innovative Manufacturing CRC
- Medical Research Council
- Australian Research Council
- National Health and Medical Research Council